Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, procedure probes, accessories, and consumable instrumentation for ophthalmology. Its products support treatment of glaucoma, diabetic macular edema, and other retinal diseases, with proprietary MicroPulse® technology used across parts of its portfolio.
Iridex news commonly covers quarterly and annual financial results, business updates, product-family activity for systems such as Cyclo G6®, retina laser platforms including PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX, and clinical literature involving MicroPulse transscleral laser therapy. Company updates also address commercial partnerships, U.S. direct sales, international distributor activity, operational efficiency measures, and Nasdaq listing-status matters.
Iridex (NASDAQ: IRIX) will participate in the Sidoti Year-End Virtual Investor Conference with management presenting on Thursday, December 11, 2025 at 10:45 AM ET. Interested parties can access a live and archived webcast via the company’s Investor Relations Event Calendar at www.IRIDEX.com. The presentation provides investors a direct opportunity to hear company updates and ask questions during the scheduled webcast.
Iridex (NASDAQ: IRIX) reported third quarter 2025 results with revenue of $12.5M, up 8% year‑over‑year, driven by higher Cyclo G6 probe and Pascal retina system sales.
Key metrics: Cyclo G6 revenue $3.5M (+13%), retina revenue $6.7M (+4%), gross profit $4.0M (32.1% margin), operating expenses $5.4M (down 12%), adjusted EBITDA loss $0.131M (improved $1.3M), and cash $5.6M (down $1.2M).
The company expects adjusted EBITDA positive for full‑year 2025 and to achieve cash flow breakeven in Q4 2025.
Iridex (Nasdaq: IRIX) will release third quarter 2025 financial results and provide a business update after market close on Tuesday, November 11, 2025. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET the same day.
Investors can join by dialing +1-888-596-4144 (US) or +1-646-968-2525 (international) and using Conference ID: 1504499. A live and recorded webcast will be posted on the company’s Investors > Event Calendar page at www.iridex.com.
Iridex Corporation (Nasdaq: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, has successfully regained compliance with Nasdaq's continued listing requirements. The company had received a non-compliance notice on May 14, 2025, due to falling below the minimum stockholders' equity requirement of $2.5 million based on their Q1 2025 10-Q filing.
On August 27, 2025, Nasdaq formally confirmed that Iridex had regained compliance with Rule 5550(b)(1) following the company's Q2 2025 10-Q filing on August 12, 2025, which demonstrated sufficient stockholders' equity. The compliance matter has been resolved and closed.
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, reported its Q2 2025 financial results. The company achieved total revenue of $13.6 million, representing 7% year-over-year growth and 14% sequential growth.
Key highlights include Cyclo G6 product family revenue of $3.3 million (flat year-over-year), with 13,100 probes and 35 laser systems sold. Retina product revenue grew 10% year-over-year to $8.0 million. The company reduced operating expenses by 28% and achieved its third consecutive quarter of positive non-GAAP adjusted EBITDA. However, gross margin declined to 34.5% from 40.7% in Q2 2024.
The company reported a net loss of $1.0 million ($0.06 per share) and maintains $6.8 million in cash. For 2025, Iridex aims to achieve cash flow breakeven and positive adjusted EBITDA with revenue consistent with 2024 levels.
Iridex (Nasdaq: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, has scheduled its second quarter 2025 financial results release for August 12, 2025 after market close.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join via phone at +1-888-596-4144 using passcode 2197032, or access the webcast through Iridex's investor relations website.
Iridex Corporation (NASDAQ: IRIX) announced the enrollment of the first patient in the independent DAME Trial, evaluating the combination of MicroPulse technology with anti-VEGF therapy for severe diabetic macular edema (DME). The UK-based study, led by Professor Noemi Lois at Queen's University Belfast, aims to enroll 264 participants across 20 clinical sites.
The trial will assess the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments to anti-VEGF therapy. The study focuses on patients with severe DME, defined by central retinal subfield thickness ≥400 μm. The research is funded by the National Institute for Health Research (NIHR) and utilizes Iridex's IQ 577® laser system with MicroPulse® treatment mode and TxCell® Scanning Delivery Device.
Iridex Corporation (Nasdaq: IRIX), a leader in laser-based medical systems for treating glaucoma and retinal diseases, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join the call by dialing +1-888-596-4144 with conference ID: 698002.
A live and recorded webcast of the event will be accessible through the "Event Calendar" page in the "Investors" section of Iridex's website at www.iridex.com.
Iridex (NASDAQ:IRIX) has released preliminary Q1 2025 financial results, showing signs of business stabilization. The company expects total revenue between $11.8-12.0 million, comparable to Q1 2024's $11.8 million.
Key operational metrics include sales of approximately 13,900 Cyclo G6 probes (up from 13,300 year-over-year) and 24 Cyclo G6 Laser Systems (up from 22). Cash and cash equivalents stood at $7.2 million as of March 29, 2025.
The company reports improved financial condition following strategic investment from Novel Inspiration International Co., , with consecutive quarterly revenue increases while reducing operating expenses. Management indicates potential for breakeven or better performance at historical revenue levels, despite exposure to external factors like tariff policy changes.